However, the identification of the molecular nature of extracellular noxious tau species is of central importance for developing an effective tau-based immunotherapy and, in this framework, the biological effects of AD-relevant NH2-truncated human tau forms outside of neurons still remain to be determined. The gene discussed is MAPT; the disease is Alzheimer disease.